Claims for Patent: 9,814,722

Summary for Patent: 9,814,722

Title:	Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
Abstract:	The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Inventor(s):	Rodgers; James D. (Landenberg, PA), Shepard; Stacey (Wilmington, DE)
Assignee:	Incyte Holdings Corporation (Wilmington, DE) Incyte Corporation (Wilmington, DE)
Application Number:	15/233,652
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,814,722
Patent Claims:	1. A method of treating a disease selected from allograft rejection and graft versus host disease in a patient in need thereof, comprising administering to the patient a compound, which is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]prop- anenitrile, or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein the compound is (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl- ]propanenitrile, or a pharmaceutically acceptable salt thereof. 3. The method of claim 2, wherein the disease is graft versus host disease. 4. The method of claim 3, wherein about 5 to about 1000 mg of the compound, or pharmaceutically acceptable salt thereof, is administered to the patient. 5. The method of claim 3, further comprising administering to the patient at least one additional therapeutic agent. 6. The method of claim 5, wherein the therapeutic agent is administered to a patient simultaneously or sequentially. 7. The method of claim 5, wherein said therapeutic agent is an immunosuppressant. 8. The method of claim 5, wherein said therapeutic agent is a steroid. 9. The method of claim 5, wherein said therapeutic agent is a corticosteroid. 10. The method of claim 9, wherein said corticosteroid is dexamethasone or prednisone. 11. The method of claim 9, wherein said corticosteroid is dexamethasone. 12. The method of claim 9, wherein said corticosteroid is prednisone. 13. The method of claim 2, wherein the disease is allograft rejection. 14. The method of claim 13, wherein about 5 to about 1000 mg of the compound, or pharmaceutically acceptable salt thereof, is administered to the patient. 15. The method of claim 13, further comprising administering to the patient at least one additional therapeutic agent. 16. The method of claim 15, wherein the therapeutic agent is administered to a patient simultaneously or sequentially. 17. The method of claim 15, wherein said therapeutic agent is an immunosuppressant. 18. The method of claim 15, wherein said therapeutic agent is a steroid. 19. The method of claim 15, wherein said therapeutic agent is a corticosteroid. 20. The method of claim 19, wherein said corticosteroid is dexamethasone or prednisone. 21. The method of claim 19, wherein said corticosteroid is dexamethasone. 22. The method of claim 19, wherein said corticosteroid is prednisone. 23. A method of treating a disease selected from allograft rejection and graft versus host disease in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of a compound, which is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]prop- anenitrile, or a pharmaceutically acceptable salt thereof. 24. The method of claim 23, wherein the compound is (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl- ]propanenitrile, or a pharmaceutically acceptable salt thereof. 25. The method of claim 24, wherein the pharmaceutical composition is suitable for oral administration. 26. The method of claim 25, wherein the pharmaceutical composition is in tablet form. 27. The method of claim 26, wherein the disease is graft versus host disease. 28. The method of claim 26, wherein the disease is allograft rejection. 29. The method of claim 24, wherein the disease is graft versus host disease. 30. The method of claim 24, wherein the disease is allograft rejection.